Stocks

Alx Oncology Holdings 

ALXONASDAQUSDHealthcare

About Alx Oncology Holdings 

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Ticker
ALXO
Trading on
NASDAQ
ISIN
-
Industry
Biotechnology
Sector
Healthcare
CEO
Jason W. Lettmann
Headquarters
323 Allerton Avenue, South San Francisco, CA, United States, 94080
Employees
48
Website
alxoncology.com

Metrics

Market cap$144M
P/E ratio-
EPS-$1.13
Dividend Yield0.00%
Beta0.56
Forward P/E ratio0
EBIDTA$-82.3M
Ex dividend date-

Analyst Insights & forecasts

Buy86%
Hold14%
Sell0%

Based on information from 7 analysts.

Average price target$4.60

Earnings per share (EPS) forecast

Q3 • 25Q4 • 25Q1 • 26Q2 • 26
Actual-$0.41-$0.37-$0.17-$0.13
Expected-$0.37-$0.35-$0.15-$0.15
Surprise-10.81%-4.88%-13.33%13.33%
MissedMissedMissedCurrent

Financial Performance

Q1 • 26Q2 • 26QoQ growth
Revenue$0M$0MNaN%
Net income$-17.9M$-18M0.25%
Profit margin-∞%-∞%NaN%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

FAQs

01How much is a Alx Oncology Holdings  share?

Alx Oncology Holdings  shares are currently traded for undefined per share.

02How many shares does Alx Oncology Holdings  have?

Alx Oncology Holdings  currently has 138M shares.

03Does Alx Oncology Holdings  pay dividends?

No, Alx Oncology Holdings  doesn't pay dividends.

04What is Alx Oncology Holdings  52 week high?

Alx Oncology Holdings  52 week high is $2.66.

05What is Alx Oncology Holdings  52 week low?

Alx Oncology Holdings  52 week low is $0.86.

06What is the 200-day moving average of Alx Oncology Holdings ?

Alx Oncology Holdings  200-day moving average is $1.81.

07Who is Alx Oncology Holdings  CEO?

The CEO of Alx Oncology Holdings  is Jason W. Lettmann.

08How many employees Alx Oncology Holdings  has?

Alx Oncology Holdings  has 48 employees.

09What is the market cap of Alx Oncology Holdings ?

The market cap of Alx Oncology Holdings  is $144M.

10What is the P/E of Alx Oncology Holdings ?

The current P/E of Alx Oncology Holdings  is null.

11What is the EPS of Alx Oncology Holdings ?

The EPS of Alx Oncology Holdings  is -$1.13.

12What is the PEG Ratio of Alx Oncology Holdings ?

The PEG Ratio of Alx Oncology Holdings  is null.

13What do analysts say about Alx Oncology Holdings ?

According to the analysts Alx Oncology Holdings  is considered a buy.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.